Highnoon Laboratories Limited (PSX:HINOON)

Market Cap	45.45B -2.6%
Revenue (ttm)	26.61B +15.6%
Net Income	3.67B +21.7%
EPS	69.33 +21.7%
Shares Out	52.98M
PE Ratio	12.37
Forward PE	13.27
Dividend	40.00 (4.66%)
Ex-Dividend Date	Apr 18, 2025

Volume	3,791
Average Volume	25,197
Open	878.95
Previous Close	867.95
Day's Range	857.00 - 878.95
52-Week Range	755.56 - 1,241.00
Beta	-0.05
RSI	41.76
Earnings Date	Apr 2, 2026

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, allergy, respiratory, and urology; and generic products under various brands. The company operates in Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, Dubai, Sudan, an...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,376
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2024, Highnoon Laboratories's revenue was 24.63 billion, an increase of 24.60% compared to the previous year's 19.77 billion. Earnings were 3.39 billion, an increase of 38.44%.